Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events (Q33865098)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events |
scientific article |
Statements
1 reference
Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events (English)
1 reference
Martin Stanulla
1 reference
Andre Franke
1 reference
Timo Gaiser
1 reference
Tobias Meißner
1 reference
Adam Mark
1 reference
Casey Williams
1 reference
Wolfgang E Berdel
1 reference
Stephanie Wiebe
1 reference
Andrea Kerkhoff
1 reference
Eva Wardelmann
1 reference
Philip Rosenstiel
1 reference
Norbert Arnold
1 reference
Brian Leyland-Jones
1 reference
Michael Forster
1 reference
5 July 2017
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference